NCT01153932 - Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

September 30, 2012

Conditions

Muscular Dystrophies

Interventions

DRUG

GSK2402968

Subcutaneous injection

DRUG

matched placebo

Subcutaneous injection

Trial Locations (13)

GSK Investigational Site, Westmead

GSK Investigational Site, Parkville

GSK Investigational Site, Ghent

GSK Investigational Site, Essen

GSK Investigational Site, Valencia

GSK Investigational Site, Paris

GSK Investigational Site, Freiburg im Breisgau

GSK Investigational Site, Jerusalem

GSK Investigational Site, Nijmegen

GSK Investigational Site, Esplugues (Barcelona)

GSK Investigational Site, Ankara

GSK Investigational Site, London

GSK Investigational Site, Newcastle upon Tyne